Koppel Adam
SEC insider (Form 3/4/5 filer). CIK 0001578965. Director & 10% Owner at Kailera Therapeutics, Inc. (KLRA) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Apr 20, 2026. Located in BOSTON, MA.
Companies Koppel Adam has filed insider reports for
- Kailera Therapeutics, Inc. (KLRA): Director, 10% Owner
- Foghorn Therapeutics Inc. (FHTX): Director
Koppel Adam
CIK: 0001578965
Transaction Breakdown
Open Market Buys (P)1 (25.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (25.0%)
Compensation grants
Other (G, F, J, C, D, …)2 (50.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Apr 20, 2026KLRA
Kailera Therapeutics, Inc.
ConversionIndirect16.9M shares- - Apr 20, 2026KLRA
Kailera Therapeutics, Inc.
ConversionIndirect4.1M shares- - Apr 20, 2026KLRA
Kailera Therapeutics, Inc.
PurchaseIndirect1.6M shares at avg. $16.00$25.0M - Apr 16, 2026KLRA
Kailera Therapeutics, Inc.
AwardDirectStock Option (right to buy)
38.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 20, 2026 |  KLRA Kailera Therapeutics, Inc. | Conversion | 16,875,000 | - | $0 | Indirect |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | Conversion | 4,145,768 | - | $0 | Indirect |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | Purchase | 1,562,500 | $16.00 | $25,000,000 | Indirect |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | Award Stock Option (right to buy) | 38,300 | - | - | Direct |
1-4 of 4 transactions